Drug-induced hypersensitivity syndrome: recent advances in drug allergy

References

• Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem. Immunol. Allergy 97, 1–17 (2012).
   PubMedGoogle Scholar
• Shiohara T, Kano Y, Takahashi R, Ishida T, Mizukawa Y. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem. Immunol. Allergy 97, 122–138 (2012).
   PubMedGoogle Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331(19), 1272–1285 (1994).
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92–96 (1993).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35–44 (2008).
   PubMed Web of Science ®Google Scholar
• Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem. Immunol. Allergy 97, 149–166 (2012).
   PubMedGoogle Scholar
• Merritt HH, Putnam TJ. Sodium diphenylhydantoinate in the treatment of convulsive disorders. JAMA 111, 1068–1073 (1938).
   Google Scholar
• Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N. Engl. J. Med. 242(23), 897–898 (1950).
   PubMed Web of Science ®Google Scholar
• Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest. 82(6), 1826–1832 (1988).
   PubMed Web of Science ®Google Scholar
• Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin. Cutan. Med. Surg. 15(4), 250–257 (1996).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch. Dermatol. 134(9), 1108–1112 (1998).
   PubMedGoogle Scholar
• Tohyama M, Yahata Y, Yasukawa M et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch. Dermatol. 134(9), 1113–1117 (1998).
   PubMedGoogle Scholar
• Tohyama M, Hashimoto K, Yasukawa M et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br. J. Dermatol. 157(5), 934–940 (2007).
   PubMed Web of Science ®Google Scholar
• Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol. Int. 55(1), 1–8 (2006).
   PubMedGoogle Scholar
• Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br. J. Dermatol. 156(5), 1083–1084 (2007).
   PubMed Web of Science ®Google Scholar
• Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br. J. Dermatol. 156(3), 609–611 (2007).
   PubMed Web of Science ®Google Scholar
• Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol. Allergy Clin. North Am. 29(3), 481–501 (2009).
   PubMed Web of Science ®Google Scholar
• Sakuma K, Kano Y, Fukuhara M, Shiohara T. Syndrome of inappropriate secretion of antidiuretic hormone associated with limbic encephalitis in a patient with drug-induced hypersensitivity syndrome. Clin. Exp. Dermatol. 33(3), 287–290 (2008).
   PubMedGoogle Scholar
• Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 23(5), 272–275 (1992).
   PubMed Web of Science ®Google Scholar
• Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch. Dermatol. 140(2), 183–188 (2004).
   PubMedGoogle Scholar
• Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpes viruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br. J. Dermatol. 155(2), 301–306 (2006).
   PubMed Web of Science ®Google Scholar
• Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 62(12), 1439–1444 (2007).
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428(6982), 486 (2004).
   PubMed Web of Science ®Google Scholar
• Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology (Basel) 215(1), 86–88 (2007).
   PubMedGoogle Scholar
• Kano Y, Hirahara K, Asano Y, Shiohara T. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm. Venereol. 88(6), 616–618 (2008).
   PubMedGoogle Scholar
• Hung S-I, Chung W-H, Liou L-B et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Kang HR, Jee YK, Kim YS et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 21, 303–307 (2011).
   PubMed Web of Science ®Google Scholar
• Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034–1041 (2011).
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134–1143 (2011).
   PubMed Web of Science ®Google Scholar
• Picard D, Janela B, Descamps V et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci. Transl. Med. 2, 46–62 (2010).
   Web of Science ®Google Scholar
• Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J. Immunol. 182(12), 8071–8079 (2009).
   PubMed Web of Science ®Google Scholar
• Kano Y, Sakuma K, Shiohara T. Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br. J. Dermatol. 156(5), 1061–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun. Rev. 8(6), 488–494 (2009).
   PubMedGoogle Scholar
• Shiohara T, Takahashi R, Kano Y. Drug-induced hypersensitivity syndrome and viral infection. In: Drug Hypersensitivity. Pichler WJ (Ed.). Karger, Basel, Switzerland, 251–266 (2007).
   Google Scholar
• Asano Y, Kagawa H, Kano Y, Shiohara T. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch. Dermatol. 145(9), 1030–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 6(2), 140–143 (2005).
   PubMed Web of Science ®Google Scholar
• Shiohara T, Kurata M, Mizukawa Y, Kano Y. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol. Int. 59(4), 333–343 (2010).
   PubMedGoogle Scholar